Upstream Bio, Inc. (UPB) Dividend History

Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing novel therapies for immune-mediated diseases. The company aims to address unmet medical needs by advancing innovative treatments through optimized clinical development and strategic partnerships.

Dividend History

Upstream Bio, Inc. currently does not pay dividends

Company News

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio presented data at the EAACI Congress showing that its novel antibody verekitug, which targets the TSLP receptor, has greater potency compared to treatments targeting the TSLP ligand. This suggests verekitug may have a differentiated profile across inflammatory diseases like severe asthma, COPD, and chronic rhinosinusitis.

GlobeNewswire Inc.

Page data last updated 08/19/2025 16:54:19 UTC